6.2.1.64 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12694406&form=6&db=m ASPP2 inhibits APP-BP1-mediated NEDD8 conjugation to cullin-1 and decreases APP-BP1-induced cell proliferation and neuronal apoptosis. causal interaction,therapeutic application,unassigned 3,4,0 6.2.1.64 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14557245&form=6&db=m APP-BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer's disease brain. causal interaction,unassigned 4,0 6.2.1.64 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20827337&form=6&db=m Amyloid Precursor Protein Binding Protein-1 Is Up-regulated in Brains of Tg2576 Mice. causal interaction,ongoing research,unassigned 4,4,0 6.2.1.64 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32579500&form=6&db=m Melatonin Prevents Neddylation Dysfunction in A?42-Exposed SH-SY5Y Neuroblastoma Cells by Regulating the Amyloid Precursor Protein- Binding Protein 1 Pathway. causal interaction,unassigned 1,0 6.2.1.64 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22457814&form=6&db=m The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. ongoing research,therapeutic application,unassigned 3,4,0 6.2.1.64 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30198810&form=6&db=m AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor. therapeutic application,unassigned 4,0 6.2.1.64 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32360865&form=6&db=m Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27Kip1. ongoing research,therapeutic application,unassigned 2,1,0 6.2.1.64 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24213570&form=6&db=m Endothelial deletion of Sag/Rbx2/Roc2 E3 ubiquitin ligase causes embryonic lethality and blocks tumor angiogenesis. causal interaction,therapeutic application,unassigned 3,2,0 6.2.1.64 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28468780&form=6&db=m Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 6.2.1.64 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33547247&form=6&db=m Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss-driven Tumorigenesis. causal interaction,therapeutic application,unassigned 2,2,0 6.2.1.64 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26592553&form=6&db=m MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma. ongoing research,unassigned 4,0 6.2.1.64 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26807316&form=6&db=m MLN4924, a Novel NEDD8-activating enzyme inhibitor, exhibits antitumor activity and enhances cisplatin-induced cytotoxicity in human cervical carcinoma: in vitro and in vivo study. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 6.2.1.64 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29434977&form=6&db=m Neddylation inhibitor MLN4924 induces G ongoing research,therapeutic application,unassigned 1,1,0 6.2.1.64 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30341788&form=6&db=m The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 6.2.1.64 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31880252&form=6&db=m Design, synthesis and biological evaluation of 4-amino substituted 2H-chromen-2-one derivatives as an NEDD8 activating enzyme inhibitor in pancreatic cancer cells. causal interaction,therapeutic application,unassigned 2,3,0 6.2.1.64 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30341788&form=6&db=m The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 6.2.1.64 Cholangiocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25229838&form=6&db=m Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target. therapeutic application,unassigned 4,0 6.2.1.64 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30402022&form=6&db=m The Nedd8-activating enzyme inhibitor MLN4924 suppresses colon cancer cell growth via triggering autophagy. therapeutic application,unassigned 3,0 6.2.1.64 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26082455&form=6&db=m Radiosensitization of Human Colorectal Cancer Cells by MLN4924: An Inhibitor of NEDD8-Activating Enzyme. ongoing research,therapeutic application,unassigned 3,1,0 6.2.1.64 Down Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17611268&form=6&db=m Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis. causal interaction,ongoing research,unassigned 2,2,0 6.2.1.64 Encephalomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33374005&form=6&db=m Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 6.2.1.64 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33374005&form=6&db=m Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 6.2.1.64 Esophageal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32398095&form=6&db=m Neddylation inhibition activates the protective autophagy through NF-?B-catalase-ATF3 Axis in human esophageal cancer cells. diagnostic usage,therapeutic application,unassigned 1,3,0 6.2.1.64 Esophageal Squamous Cell Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29434977&form=6&db=m Neddylation inhibitor MLN4924 induces G ongoing research,therapeutic application,unassigned 1,1,0 6.2.1.64 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31941714&form=6&db=m Hepatic neddylation targets and stabilizes electron transfer flavoproteins to facilitate fatty acid ?-oxidation. causal interaction,unassigned 2,0 6.2.1.64 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31044422&form=6&db=m Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 6.2.1.64 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31771104&form=6&db=m The Protein Neddylation Inhibitor MLN4924 Suppresses Patient-Derived Glioblastoma Cells via Inhibition of ERK and AKT Signaling. unassigned - 6.2.1.64 Graft vs Host Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27815049&form=6&db=m Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice. ongoing research,therapeutic application,unassigned 4,4,0 6.2.1.64 Head and Neck Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21914854&form=6&db=m The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. causal interaction,therapeutic application,unassigned 2,3,0 6.2.1.64 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24900352&form=6&db=m Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity. causal interaction,therapeutic application,unassigned 4,4,0 6.2.1.64 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32059437&form=6&db=m ABCG2 Overexpression Contributes to Pevonedistat Resistance. causal interaction,therapeutic application,unassigned 3,4,0 6.2.1.64 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33089874&form=6&db=m Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 6.2.1.64 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30586159&form=6&db=m Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus. therapeutic application,unassigned 4,0 6.2.1.64 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21386696&form=6&db=m Focal transient ischemia increases APP-BP1 expression in neural progenitor cells. ongoing research,unassigned 4,0 6.2.1.64 Ischemic Attack, Transient http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21386696&form=6&db=m Focal transient ischemia increases APP-BP1 expression in neural progenitor cells. ongoing research,unassigned 4,0 6.2.1.64 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22110742&form=6&db=m Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid. diagnostic usage,ongoing research,unassigned 3,3,0 6.2.1.64 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31349760&form=6&db=m The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 6.2.1.64 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33503305&form=6&db=m Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. diagnostic usage,therapeutic application,unassigned 3,4,0 6.2.1.64 Leukemia, Lymphocytic, Chronic, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24634471&form=6&db=m The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-?B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells. causal interaction,therapeutic application,unassigned 3,1,0 6.2.1.64 Leukemia, Lymphocytic, Chronic, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27528738&form=6&db=m Correction: The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-?B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells. causal interaction,therapeutic application,unassigned 3,1,0 6.2.1.64 Leukemia, Lymphocytic, Chronic, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32203139&form=6&db=m Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells. causal interaction,therapeutic application,unassigned 4,1,0 6.2.1.64 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20203261&form=6&db=m Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. causal interaction,therapeutic application,unassigned 4,4,0 6.2.1.64 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25971362&form=6&db=m Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. therapeutic application,unassigned 2,0 6.2.1.64 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26045051&form=6&db=m MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. diagnostic usage,therapeutic application,unassigned 1,3,0 6.2.1.64 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28157218&form=6&db=m Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,3 6.2.1.64 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29348128&form=6&db=m Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. causal interaction,therapeutic application,unassigned 2,2,0 6.2.1.64 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33420360&form=6&db=m TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia. causal interaction,therapeutic application,unassigned 1,1,0 6.2.1.64 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33503305&form=6&db=m Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. diagnostic usage,therapeutic application,unassigned 3,4,0 6.2.1.64 Leukemia, Myelomonocytic, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33503305&form=6&db=m Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. diagnostic usage,therapeutic application,unassigned 3,4,0 6.2.1.64 Liver Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22562464&form=6&db=m The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. therapeutic application,unassigned 1,0 6.2.1.64 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20525923&form=6&db=m MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. causal interaction,therapeutic application,unassigned 3,3,0 6.2.1.64 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25782162&form=6&db=m Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells. ongoing research,therapeutic application,unassigned 3,4,0 6.2.1.64 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26561559&form=6&db=m Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. ongoing research,therapeutic application,unassigned 2,3,0 6.2.1.64 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26675347&form=6&db=m Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. ongoing research,therapeutic application,unassigned 4,3,0 6.2.1.64 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33073261&form=6&db=m Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma. ongoing research,therapeutic application,unassigned 2,4,0 6.2.1.64 Lymphoma, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20525923&form=6&db=m MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. causal interaction,therapeutic application,unassigned 3,3,0 6.2.1.64 Lymphoma, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30101447&form=6&db=m Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma. therapeutic application,unassigned 4,0 6.2.1.64 Lymphoma, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33073261&form=6&db=m Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma. ongoing research,therapeutic application,unassigned 2,4,0 6.2.1.64 Lymphoma, Large B-Cell, Diffuse http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20525923&form=6&db=m MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. causal interaction,therapeutic application,unassigned 3,3,0 6.2.1.64 Lymphoma, Large B-Cell, Diffuse http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30101447&form=6&db=m Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma. therapeutic application,unassigned 4,0 6.2.1.64 Lymphoma, Large B-Cell, Diffuse http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33073261&form=6&db=m Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma. ongoing research,therapeutic application,unassigned 2,4,0 6.2.1.64 Lymphoma, Mantle-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26675347&form=6&db=m Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. ongoing research,therapeutic application,unassigned 4,3,0 6.2.1.64 Lymphoma, Non-Hodgkin http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32203139&form=6&db=m Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells. causal interaction,therapeutic application,unassigned 4,1,0 6.2.1.64 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22502714&form=6&db=m Inhibition of the NEDD8 conjugation pathway by shRNA to UBA3, the subunit of the NEDD8-activating enzyme, suppresses the growth of melanoma cells. unassigned - 6.2.1.64 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27056178&form=6&db=m A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. ongoing research,therapeutic application,unassigned 2,3,0 6.2.1.64 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27783255&form=6&db=m Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). therapeutic application,unassigned 2,0 6.2.1.64 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26561559&form=6&db=m Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. ongoing research,therapeutic application,unassigned 2,3,0 6.2.1.64 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31406107&form=6&db=m The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death. therapeutic application,unassigned 3,0 6.2.1.64 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31583781&form=6&db=m Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor ?B pathways. causal interaction,unassigned 4,0 6.2.1.64 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34482362&form=6&db=m Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition. unassigned - 6.2.1.64 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25733005&form=6&db=m Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,3,0 6.2.1.64 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28157218&form=6&db=m Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,3 6.2.1.64 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33503305&form=6&db=m Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. diagnostic usage,therapeutic application,unassigned 3,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19360080&form=6&db=m An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. causal interaction,therapeutic application,unassigned 4,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20129059&form=6&db=m Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. diagnostic usage,unassigned 1,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21159650&form=6&db=m NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. therapeutic application,unassigned 3,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21487042&form=6&db=m Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. causal interaction,ongoing research,therapeutic application,unassigned 2,3,1,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21677879&form=6&db=m Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. ongoing research,therapeutic application,unassigned 2,1,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22439935&form=6&db=m Treatment-emergent mutations in NAE? confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. therapeutic application,unassigned 4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22799561&form=6&db=m MLN4924 : a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. causal interaction,therapeutic application,unassigned 3,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22832224&form=6&db=m A Gatekeeper Residue for NEDD8-Activating Enzyme Inhibition by MLN4924. therapeutic application,unassigned 4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22874562&form=6&db=m Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells. causal interaction,unassigned 2,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23066438&form=6&db=m Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases. causal interaction,therapeutic application,unassigned 1,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23995842&form=6&db=m Ubiquitin E3 Ligase CRL4CDT2/DCAF2 as a Potential Chemotherapeutic Target for Ovarian Surface Epithelial Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24155378&form=6&db=m A first-in-class NAE inhibitor, MLN4924, blocks lentiviral infection in myeloid cells by disrupting neddylation-dependent Vpx-mediated SAMHD1 degradation. therapeutic application,unassigned 3,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24232190&form=6&db=m Applications of pathology-assisted image analysis of immunohistochemistry-based biomarkers in oncology. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24857708&form=6&db=m Effective virtual screening strategy toward covalent ligands: identification of novel NEDD8-activating enzyme inhibitors. causal interaction,therapeutic application,unassigned 3,1,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25196325&form=6&db=m Discovery of deoxyvasicinone derivatives as inhibitors of NEDD8-activating enzyme. causal interaction,therapeutic application,unassigned 3,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25615422&form=6&db=m MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies. therapeutic application,unassigned 4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25899169&form=6&db=m Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications. causal interaction,therapeutic application,unassigned 3,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25904638&form=6&db=m Suppression of glioblastoma by targeting the overactivated protein neddylation pathway. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26423795&form=6&db=m Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,2,3 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26675347&form=6&db=m Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. ongoing research,therapeutic application,unassigned 4,3,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26807316&form=6&db=m MLN4924, a Novel NEDD8-activating enzyme inhibitor, exhibits antitumor activity and enhances cisplatin-induced cytotoxicity in human cervical carcinoma: in vitro and in vivo study. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26807320&form=6&db=m Molecular dynamics simulation on the low sensitivity of mutants of NEDD-8 activating enzyme for MLN4924 inhibitor as a cancer drug. therapeutic application,unassigned 4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27224919&form=6&db=m Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27333051&form=6&db=m Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27602774&form=6&db=m Circadian clock components ROR? and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28177892&form=6&db=m Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis. therapeutic application,unassigned 3,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28388520&form=6&db=m Discovery of benzothiazole derivatives as novel non-sulfamide NEDD8 activating enzyme inhibitors by target-based virtual screening. causal interaction,unassigned 4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28468780&form=6&db=m Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28717191&form=6&db=m MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma. diagnostic usage,unassigned 1,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28717502&form=6&db=m An inhibitor of ubiquitin conjugation and aggresome formation. causal interaction,therapeutic application,unassigned 3,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29781056&form=6&db=m Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. ongoing research,therapeutic application,unassigned 2,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30586948&form=6&db=m MLN4924, a Protein Neddylation Inhibitor, Suppresses the Growth of Human Chondrosarcoma through Inhibiting Cell Proliferation and Inducing Endoplasmic Reticulum Stress-Related Apoptosis. therapeutic application,unassigned 4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30892082&form=6&db=m MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling. causal interaction,therapeutic application,unassigned 4,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30943988&form=6&db=m Neddylation: a novel modulator of the tumor microenvironment. therapeutic application,unassigned 3,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31092565&form=6&db=m TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models. causal interaction,therapeutic application,unassigned 1,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31404297&form=6&db=m An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer. causal interaction,diagnostic usage,unassigned 3,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31898235&form=6&db=m Targeting Protein Neddylation for Cancer Therapy. therapeutic application,unassigned 1,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31907687&form=6&db=m Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment. causal interaction,ongoing research,unassigned 1,1,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32059437&form=6&db=m ABCG2 Overexpression Contributes to Pevonedistat Resistance. causal interaction,therapeutic application,unassigned 3,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32714568&form=6&db=m Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer. causal interaction,therapeutic application,unassigned 4,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32721435&form=6&db=m The NEDD8-activating enzyme inhibition with MLN4924 sensitizes human cancer cells of different origins to apoptosis and necroptosis. ongoing research,therapeutic application,unassigned 3,2,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33089874&form=6&db=m Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33129593&form=6&db=m Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo. therapeutic application,unassigned 4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33503305&form=6&db=m Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. diagnostic usage,therapeutic application,unassigned 3,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33560503&form=6&db=m A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors. ongoing research,therapeutic application,unassigned 3,2,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33898451&form=6&db=m Advances in Cancer Treatment by Targeting the Neddylation Pathway. causal interaction,therapeutic application,unassigned 4,4,0 6.2.1.64 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34359705&form=6&db=m Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways. causal interaction,therapeutic application,unassigned 1,2,0 6.2.1.64 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34207315&form=6&db=m The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. therapeutic application,unassigned 4,0 6.2.1.64 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23939375&form=6&db=m Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924. diagnostic usage,ongoing research,unassigned 1,4,0 6.2.1.64 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29387232&form=6&db=m MLN4924 neddylation inhibitor promotes cell death in paclitaxel-resistant human lung adenocarcinoma cells. causal interaction,therapeutic application,unassigned 1,2,0 6.2.1.64 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22072567&form=6&db=m Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. ongoing research,therapeutic application,unassigned 3,1,0 6.2.1.64 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31404297&form=6&db=m An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer. causal interaction,diagnostic usage,unassigned 3,4,0 6.2.1.64 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31880252&form=6&db=m Design, synthesis and biological evaluation of 4-amino substituted 2H-chromen-2-one derivatives as an NEDD8 activating enzyme inhibitor in pancreatic cancer cells. causal interaction,therapeutic application,unassigned 2,3,0 6.2.1.64 Perinatal Death http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31941714&form=6&db=m Hepatic neddylation targets and stabilizes electron transfer flavoproteins to facilitate fatty acid ?-oxidation. causal interaction,unassigned 2,0 6.2.1.64 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26993774&form=6&db=m The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia. causal interaction,therapeutic application,unassigned 3,3,0 6.2.1.64 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27626202&form=6&db=m The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2? and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia. causal interaction,ongoing research,unassigned 2,1,0 6.2.1.64 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27224919&form=6&db=m Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 6.2.1.64 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28838998&form=6&db=m The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors. therapeutic application,unassigned 3,0 6.2.1.64 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30341788&form=6&db=m The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 6.2.1.64 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34258028&form=6&db=m A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811). therapeutic application,unassigned 4,0 6.2.1.64 Xeroderma Pigmentosum http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33381997&form=6&db=m Spironolactone-induced XPB degradation requires TFIIH integrity and ubiquitin-selective segregase VCP/p97. causal interaction,therapeutic application,unassigned 1,1,0